Teva Pharmaceutical Industries Limited and BioCryst Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis

Pharma Giants' Revenue: A Decade of Divergence

__timestampBioCryst Pharmaceuticals, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 20141360800020272000000
Thursday, January 1, 20154825700019652000000
Friday, January 1, 20162635300021903000000
Sunday, January 1, 20172518600022385000000
Monday, January 1, 20182065300018854000000
Tuesday, January 1, 20194883500016887000000
Wednesday, January 1, 20201781200016658000000
Friday, January 1, 202115717000015878000000
Saturday, January 1, 202227082700014925000000
Sunday, January 1, 202333141200015846000000
Monday, January 1, 202416544000000
Loading chart...

Infusing magic into the data realm

A Tale of Two Pharmaceutical Giants: Revenue Trends from 2014 to 2023

In the ever-evolving pharmaceutical industry, Teva Pharmaceutical Industries Limited and BioCryst Pharmaceuticals, Inc. have showcased contrasting revenue trajectories over the past decade. From 2014 to 2023, Teva's revenue experienced a decline of approximately 22%, dropping from its peak in 2017. This trend reflects the challenges faced by the company in maintaining its market dominance. In contrast, BioCryst Pharmaceuticals has seen a remarkable growth, with its revenue increasing by over 2300% during the same period, highlighting its successful strategic initiatives and product innovations.

The data reveals that while Teva's revenue peaked in 2017, BioCryst's revenue surged significantly post-2020, marking a pivotal shift in the competitive landscape. This analysis underscores the dynamic nature of the pharmaceutical sector, where innovation and adaptability are key to sustained growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025